Acceleron Pharma
Acceleron Pharma Q3 FY19: revenue $4.2M
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001280600-19-000052
- Document
- 10-Q
Key figures from this report
These are the numbers Acceleron Pharma reported for Q3 FY19, the quarter ended Sep 30, 2019, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$4.2MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Net income−$45.4MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Cash and cash equivalents$169.5MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
- Cash from operations−$37.0MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Same SIC code (2836) and public float not reported.
- Adaptimmune Therapeutics ADAP
- Adverum Biotechnologies ADVM
- AgomAb Therapeutics AGMB
- Alvotech ALVO
- Argenx ARGX
